INTRODUCTION {#s1}
============

Epidermal growth factor receptor (EGFR), also known as ErbB1 or HER1, together with three homologues (HER2, HER3 and HER4) composes the ErbB family of tyrosine kinase receptors (TRKs). EGFR represents a transmembrane receptor with a molecular weight of 175 kDa. Upon binding to its ligands such as epidermal growth factor (EGF) or transforming growth factor-α (TGF-α), EGFR homo- or hetero-dimerizes with its counterparts \[[@R1]\]. Such dimerization stimulates auto-phosphorylation of several tyrosine residues in its intracellular kinase domain, which further activates downstream transduction cascades, *e.g.* PI3K/AKT, MAPK/ERK and PLCγ1/PKC to exert cell proliferation and differentiation effect \[[@R2]\].

Signal transduction of EGFR is ordinarily under intimate control in human beings. However, tumor patients tend to display deregulated EGFR activity, mostly due to point mutations, exon 8 deletion or gene amplification \[[@R3]--[@R5]\]. Abnormal enhancement of EGFR activity represents a carcinogenesis initiator. In this context, the enormous relevance of anti-EGFR strategy *e.g*. small molecule tyrosine kinase inhibitors (TKI) gefitinib or monoclonal antibodies panitumumab and their clinical implication gained great success in the past years \[[@R6]\].

Besides functioning as carcinogenesis initiator, excessive EGFR activity is also considered to affect subsequent malignant development. Despite its unambiguous role as oncogene, the documentation of its clinical relevance is surprisingly heterogeneous in the scientific literature \[[@R7]\]. In the present investigation, we estimated the association of EGFR with clinical outcomes and pathological parameters at both mRNA and protein levels. We assessed *EGFR* mRNA expression and its correlation with overall survival (OS), TNM stage and grade of patients from 30 datasets covering 15 cancer types and compared 30 studies in this regard. We also performed immunohistochemical analysis on 502 human cases covering 27 tumor types and studied the correlation between EGFR protein expression and clinical outcomes or pathological characteristics corresponding to membranous and cytoplasmic or nuclear expression pattern as explanatory variable due to the fact that granular EGFR expression in the nucleus has been described as a factor of resistance to chemo- and radiotherapy \[[@R8]--[@R10]\]. Here, we integrated this information and considered, how it might be best applied for clinical routine diagnosis.

RESULTS {#s2}
=======

Correlation of *EGFR* mRNA expression and clinical outcomes {#s2_1}
-----------------------------------------------------------

Thirty datasets were screened with filters in the Oncomine database. The filter flow is shown in Figure [1](#F1){ref-type="fig"}. Among 30 datasets (Tables [1](#T1){ref-type="table"}--[3](#T3){ref-type="table"}), 23 datasets (=76.7%) did not show any significant association between *EGFR* mRNA level and clinical outcome or pathological characteristics of patients, except datasets GSE22226 and GSE10846, which showed significant associations between high *EGFR* mRNA expression levels and poor overall survival (cutoff mean, *p* = 0.03; cutoff mean, *p* = 0.03; respectively) (Table [1](#T1){ref-type="table"}). However, adverse effects were documented in datasets GSE4412 and GSE15081 with statistical significance (cutoff median = mean, *p* = 0.02; cutoff median, probe AGhsB031519, *p* = 0.04), which indicated that high *EGFR* mRNA expression level was correlated with better overall survival.

![Filter flow for datasets screen](oncotarget-10-1918-g001){#F1}

###### Correlation of EGFR mRNA expression and overall survival

  Cancer type   GEO accession   Jetset probe    OS (*p* value)   
  ------------- --------------- --------------- ---------------- ----------
  Bladder       GSE13507        ILMN_1696521    0.47             0.25
  Brain         GSE7696         211607_x\_at    0.12             0.28
                GSE4271         211607_x\_at    0.19             0.19
                GSE4412         211607_x\_at    0.02^\*^         0.02^\*^
  Breast        GSE22226        A_23_P215790    0.07             0.03^\*^
                GSE20685        211607_x\_at    0.72             0.54
  Colorectal    GSE17536        211607_x\_at    0.01             0.01
  Gastric       GSE15081        AGhsA201212     0.52             0.32
                                AGhsB031519     0.04^\*^         0.11
  Head-Neck     GSE2379         1537_at         0.07             0.27
                GSE65858        ILMN_1696521    0.88             0.28
  Leukemia      GSE12417        211607_x\_at    0.17             0.14
  Liver         GSE10186        DAP2_6059       0.12             0.08
                GSE364          NM_005228       0.33             0.28
  Lung          GSE19188        211607_x\_at    0.93             0.46
                GSE31210        211607_x\_at    0.64             0.96
                GSE5123         X00588          0.50             0.61
                GSE4573         211607_x\_at    0.22             0.27
  Lymphoma      GSE4475         211607_x\_at    0.53             0.76
                GSE10846        211607_x\_at    0.08             0.03^\*^
  Melanoma      GSE8401         211607_x\_at    0.64             0.47
                GSE2658         211607_x\_at    0.59             0.52
                GSE19234        211607_x\_at    0.97             0.60
  Ovarian       GSE26712        211607_x\_at    0.65             0.65
                GSE9899         211607_x\_at    0.68             0.84
                GSE14764        211607_x\_at    0.93             0.66
  Pancreas      GSE17891        211607_x\_at    0.95             0.89
  Prostate      GSE6919         1537_at         0.67             0.67
                GSE10645        GI_29725608-S   0.43             0.51
  Renal         GSE3538         AA234715        0.59             0.26
                                W48712          0.20             0.20
                                H80438          0.94             0.99

*P* value \< 0.05 was labeled with asterisk mark. OS, overall survival. Median, group EGFR mRNA expression as "high" and "low" by median. Mean, group EGFR mRNA expression as "high" and "low" by mean.

Regarding tumor grade, datasets GSE5206 and GSE3538 showed a significant correlation between high *EGFR* mRNA expression and poor differentiation (cutoff median, *p* = 0.03; cutoff median = mean, *p* = 0.02; respectively) (Table [2](#T2){ref-type="table"}). Conversely, dataset GSE4412 indicated a conflicting trend (cutoff median = mean, *p*=0.02). In addition, dataset GSE15081 conveyed a trend for association of *EGFR* mRNA with N stage, GSE3538 with grade (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}).

###### Correlation of EGFR mRNA expression and grade

  Cancer type   GEO accession   Jetset probe   Grade (*p* value)   
  ------------- --------------- -------------- ------------------- ----------
  Bladder       GSE13507        ILMN_1696521   0.86                0.81
  Brain         GSE4271         211607_x\_at   0.35                0.35
                GSE4412         211607_x\_at   0.02^\*^            0.02^\*^
  Breast        GSE22226        A_23_P215790   0.06                0.05
  Colorectal    GSE17536        211607_x\_at   0.06                0.10
                GSE5206         211607_x\_at   0.03^\*^            0.08
  Gastric       GSE15081        AGhsA201212    0.08                0.17
                                AGhsB031519    0.64                0.23
  Head-Neck     GSE2379         1537_at        0.54                0.63
  Liver         GSE364          NM_005228      0.19                0.16
  Lung          GSE5123         X00588         0.38                0.08
                GSE4573         211607_x\_at   0.46                0.42
  Ovarian       GSE9899         211607_x\_at   0.05                0.02^\*^
                GSE14764        211607_x\_at   0.83                0.85
  Pancreas      GSE17891        211607_x\_at   0.37                0.85
  Renal         GSE3538         AA234715       0.36                0.28
                                W48712         0.02^\*^            0.02^\*^
                                H80438         0.34                0.36

*P* value \< 0.05 was labeled with asterisk mark. Median, group EGFR mRNA expression as "high" and "low" by median. Mean, group EGFR mRNA expression as "high" and "low" by mean.

###### Correlation of EGFR mRNA expression and TNM stage

  Cancer type   GEO accession   Jetset probe    T (*p* value)   N (*p* value)   M (*p* value)                 
  ------------- --------------- --------------- --------------- --------------- --------------- ------ ------ ------
  Bladder       GSE13507        ILMN_1696521    0.56            0.47            0.08            0.31   0.66   0.53
  Breast        GSE22226        A_23_P215790    0.29            0.26                                          
                GSE20685        211607_x\_at    0.92            0.98            0.59            0.60   0.48   0.14
  Colorectal    GSE5206         211607_x\_at    0.63            0.78            0.68            0.59   0.73   0.62
  Gastric       GSE15081        AGhsA201212                                     0.02^\*^        0.10          
                                AGhsB031519                                     0.35            0.97          
  Head-Neck     GSE2379         1537_at         0.25            0.24            0.55            0.48          
                GSE65858        ILMN_1696521    0.26            0.11            0.13            0.09   0.25   0.09
  Liver         GSE364          NM_005228                                                              0.46   0.73
  Lung          GSE5123         X00588                                          0.63            0.65   0.23   0.12
                GSE4573         211607_x\_at    0.56            0.45            0.60            0.38          
  Melanoma      GSE8401         211607_x\_at    0.32            0.25            0.38            0.73   0.12   0.08
  Pancreas      GSE17891        211607_x\_at    0.97            0.46            0.87            0.42          
  Prostate      GSE6919         1537_at         0.32            0.32            0.61            0.61          
                GSE10645        GI_29725608-S   0.34            0.28            0.84            0.51          

*P* value \< 0.05 was labeled with asterisk mark. T, N and M represented T stage, N stage and M stage, respectively. Median, group EGFR mRNA expression as "high" and "low" by median. Mean, group EGFR mRNA expression as "high" and "low" by mean.

Since *EGFR* mRNA expression did not correlate with survival times of patients, we were interested to analyze, whether or not EGFR protein expression was of prognostic value.

Survey of immunohistochemical studies {#s2_2}
-------------------------------------

Thirty studies filtered with following keywords "EGFR", "expression", "predictor", "biomarker" and "prognosis/prognostic" were included in our survey (Table [4](#T4){ref-type="table"}). Eighteen studies (=60%) revealed that high EGFR protein expression significantly correlated with poor clinical outcome parameters, *e.g.* overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), as well as poor pathological characteristics, *e.g.* TNM stage, grade or overall stage of patients. The other studies claimed no significant correlations.

###### Survey of immunohistochemical studies

  Citation                          OS            PFS         DFS           T             N             M       Grade       Stage
  --------------------------------- ------------- ----------- ------------- ------------- ------------- ------- ----------- -------------
  J. Tol *et al*., 2010             0.210         0.260                                                                     
  E. Despierre *et al*., 2015       0.273         0.835                                                                     
  W. Hwangbo *et al*., 2013         NS                                                                                      
  D. Dionysopoulos *et al*., 2013   NS                        NS                                                            
  D. Swinson *et al*., 2004         0.720                                                                                   
  F. Hirsch *et al*., 2003          0.220                                   0.680         0.070                             0.170
  J.-P. Spano *et al*., 2005        0.780                                   0.006^\*^     0.120         0.880   0.590       
  J. Lee *et al*., 2002             NS                                      0.270                               0.390       
  J. McKay *et al*., 2002           0.230                                                 0.800                 0.014       NS
  F. Projetti *et al*., 2013        NS            NS                                                                        
  L. Dova *et al*., 2007            NS                                                                                      
  A. Ema *et al*., 2015             0.039^\*^                               0.400         0.036^\*^                         0.012^\*^
  A. gatsuma *et al*., 2015         \<0.001^\*^                             \<0.001^\*^   \<0.001^\*^                       \<0.001^\*^
  A. Hyogotani *et al*., 2012       0.019^\*^                                                                   0.004^\*^   0.001^\*^
  S. Wheeler *et al*., 2012                       0.019^\*^                                                                 
  M. Parvin *et al*., 2016                                                  0.480         0.067         0.856   0.270       
  G. Lazaridis *et al*., 2014       0.016^\*^                                                                               
  H. Park *et al*., 2014                                      0.743         0.388         0.300                 0.331       0.018^\*^
  I. Kallel *et al*., 2012          0.004^\*^                               0.041^\*^                           0.038^\*^   
  C.-W. Huang *et al*., 2013        \<0.001^\*^               \<0.001^\*^   0.531         0.755                 0.028^\*^   0.928
  W. Jia *et al*., 2016             0.035^\*^                 0.046^\*^     0.022^\*^     0.000^\*^             0.322       0.000^\*^
  C. Hedner *et al*., 2016          0.016^\*^                               0.712         0.917         0.299   0.924       
  A. Atmaca *et al*., 2012          0.463         0.185                                                                     
  A. Gröbe *et al*., 2014                         0.830                     0.202         0.024^\*^             0.130       
  P. Zhang *et al*., 2015           0.046^\*^                               0.005^\*^     0.278                             0.001^\*^
  N. Bassullu *et al*., 2012        NS                                                                          0.039^\*^   
  M. Katurić *et al*., 2014         0.022^\*^                                                                               
  A. Noske *et al*., 2011           0.002^\*^                                                                               
  D. Weber *et al*., 2012                         0.050^\*^                                                                 
  G. Dorđević *et al*., 2012        0.046^\*^                               0.354                                           

Abbreviations: OS, overall survival; PFS, progression free survival; DFS, disease free survival; NS, not significant, but the article did not provide exact data; *P* value \< 0.05 was labeled with asterisk mark.

Compared to rather poor prognostic value *EGFR* mRNA expression, EGFR protein expression was of superior utility. Likewise, more significant associations with pathological characteristics were observed.

Correlation of EGFR protein expression and pathological parameters {#s2_3}
------------------------------------------------------------------

To validate whether EGFR protein expression and specifically its expression pattern as mcEGFR or nEGFR may provide paired associations with pathological characteristics, we conducted immunohistochemistry on a total number of 502 cases covering 27 tumor types.

Among all cases, the frequency of negative, weak, moderate and strong staining was 36.25%, 30.08%, 27.89% and 5.78% for mcEGFR, while 48.24%, 26.13%, 15.08%, 10.55% of the tumors revealed nEGFR (Figure [2](#F2){ref-type="fig"}).

![Immunohistochemical staining\
(**A**), Negative mcEGFR, breast tumor, 20×magnification; (**B**), Weak mcEGFR, kidney tumor, 20×magnification; (**C**), Moderate mcEGFR, lung tumor, 20×magnification; (**D**), Strong mcEGFR, esophagus tumor, 20×magnification; (**E**), Negative nEGFR, colon tumor, 40×magnification; (**F**), Weak nEGFR, colon tumor, 40×magnification; (**G**), Moderate nEGFR, kidney tumor, 40×magnification; (**H**), Strong nEGFR, kidney tumor, 40×magnification.](oncotarget-10-1918-g002){#F2}

Based on our investigation, higher expression of both mcEGFR and nEGFR was accompanied with lower occurrence (Figure [3](#F3){ref-type="fig"}). In other words, extreme high EGFR expression regardless of membrane-bound or nuclear expression patterns was rather rare among the tumors investigated.

![Distribution of mcEGFR and nEGFR among all tumor types\
(**A**), histogram of H-score, as indicator of mcEGFR expression, distribution among all 502 biopsies. (**B**), histogram of nEGFR distribution among all 398 biopsies. 0, 1, 2 and 3 on x-axis in histogram of nEGFR level indicated negative, weak, moderate and strong expression respectively.](oncotarget-10-1918-g003){#F3}

Furthermore, we identified the distribution of mcEGFR and nEGFR expression in different tumor types (Figure [4](#F4){ref-type="fig"}). As shown in Figure [4A](#F4){ref-type="fig"}, mcEGFR was highly expressed in brain tumors followed by lung tumors. Compared to lung tumors, the expression in brain tumors tend to be more intensive if the whisker range was put into consideration. Uterus, colorectal and kidney tumors expressed mcEGFR in a similar manner. Breast, ovary, pancreas and prostate tumors revealed comparatively low expression levels. Noticeably, there were a few cases of breast tumors with strong mcEGFR expression, which exceeded the whisker range. Tumor types comprising less than 5 cases were classified as "others" (Figure [4B](#F4){ref-type="fig"}), among which fallopian tube tumor ranked top while parotid and testis ranked the lowest. However, the results could not provide accurate information due to limited case number. In the case of nEGFR, brain tumors were excluded from analysis due to the difficulty in determining nEGFR in this tumor entity. By contrast, nEGFR was frequently found in lung tumors followed by kidney, colorectum, pancreas, ovary and uterus, respectively (Figure [4C](#F4){ref-type="fig"}). In addition, stomach tumors also expressed high nEGFR (Figure [4D](#F4){ref-type="fig"}). However, nEGFR expression in breast and prostate was comparatively rare.

![Distribution of EGFR in different tumor tissue types\
(**A**), H-score, as indicator of mcEGFR expression, distribution in different tumor types. All the tumor types comprising less than 5 cases were grouped as "others". Tissue types were color coded as shown in legend. (**B**), H-score distribution among "others". In this figure, cases of each tumor type were less than 5. Plot was drawn according to H-score and tumor types. Tissue types were color coded as shown in legend. (**C**), Distribution of nEGFR among different tumor types. nEGFR levels were classified as "Negative", "Weak", "Moderate" and "Strong" and each level was coded with green, light yellow, yellow and orange respectively. (**D**), nEGFR expression among tumor types with less than 5 cases. Heat map was drawn according to nEGFR level and tissue type. 3-Color scale indicated frequency of nEGFR expression where green showed 0 case, yellow showed 1 case while orange showed 2 cases. Detailed information about "others" refers to [Supplementary Table 2](#SD1){ref-type="supplementary-material"}.](oncotarget-10-1918-g004){#F4}

To explore the relationship between mcEGFR and nEGFR, we performed independent *t*-tests with negative or positive expression of nEGFR as grouping variable. Furthermore, we categorized the H-score as described above into four levels. Pearson\'s χ2-test was applied to assess the independence between H-score levels and nEGFR levels (Table [5](#T5){ref-type="table"}). The result provided a compelling argument that mcEGFR and nEGFR are dependent factors (*p* \< 0.001). Besides, there was a significant difference of H-score mean value between negative nEGFR and positive nEGFR groups (*p* \< 0.001) which indicated cases harboring negative nEGFR also showed lower mcEGFR expression compared to positive nEGFR cases.

###### Correlation between mcEGFR and nEGFR

  mcEGFR No. patients (% within H-score)                                                                                                           
  ---------------------------------------- ---------- ----------- ------------ ------------ ------------- --------------- ------------ ----------- --
  nEGFR                                    Negative   37.416                   Negative     115 (70.12)   54 (46.55)      21 (21.43)   2 (10.00)   
  Positive                                 101.528                Weak         23 (14.02)   35 (30.17)    40 (40.82)      6 (30.00)                
                                           Moderate   12 (7.32)   18 (15.52)   22 (22.45)   8 (40.00)                                              
  8.44E--11^\*^                            Strong     14 (8.54)   9 (7.76)     15 (15.31)   4 (20.00)     2.85E--13^\*^                            

*P* value \< 0.05 was labeled with asterisk mark.

To further explore the correlation of EGFR protein expression and pathological characteristics, we firstly run ANOVA mean comparison test for mcEGFR H-score, TNM stage and grade, respectively. Then, we used Pearson\'s χ2-test to determine the independence of H-score as negative and positive groups with TNM stage and grade, respectively. Unexpectedly, there was an adverse association between mcEGFR and T stage as mean comparison (Figure [5](#F5){ref-type="fig"}, *p* \< 0.001). In addition, H-score and T stage were dependent in an adverse manner as well (*p* \< 0.001). Moreover, positive mcEGFR was associated with low grade (*p* = 0.027) in Pearson\'s χ2-test. The same trend was also found in one-way ANOVA mean comparison test but without significance (*p* = 0.233). However, no significant difference was found among any other pathological parameters. Neither were any dependent relationships in between these parameters (Table [6](#T6){ref-type="table"}). Interestingly, nEGFR revealed consistent results that its expression and T stage was adversely dependent (*p* = 0.004) by Pearson\'s χ2-test (Table [6](#T6){ref-type="table"}).

![Correlation between H-score and T stage\
T stage was color coded as green represented T1 stage, light yellow T2, yellow T3 while orange T4.](oncotarget-10-1918-g005){#F5}

###### Correlation of EGFR protein expression and pathological characteristics

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
                     mcEGFR No. patients\                 nEGFR No. patients\                                                                                 
                     (% within pathological parameters)   (% within pathological parameters)                                                                  
  --------- -------- ------------------------------------ ------------------------------------ ----------- -------------- ----------- ----------- ----------- -------
  T Stage   T1       104.460                                                                   14(15.7)    75(84.3)                   26(39.4)    40(60.6)    

  T2        70.918                                        55(41.7)                             77(58.3)                   58(54.2)    49(45.8)                

  T3        72.144                                        46(40.0)                             69(60.0)                   40(40.4)    59(59.6)                

  T4        46.390   3.18E-05^\*^                         37(61.7)                             23(38.3)    2.19E-07^\*^   32(68.1)    15(31.9)    0.004^\*^   

  N Stage   N0       63.121                                                                    100(47.2)   112(52.8)                  93(55.4)    75(44.6)    

  N1        67.407                                        36(46.8)                             41(53.2)                   31(44.3)    39(55.7)                

  N2        73.402   0.812                                5(29.4)                              12(70.6)    0.365          7(63.6)     4(36.4)     0.224       

  M Stage   M0       72.587                                                                    133(39.9)   200(60.1)                  134(50.2)   133(49.8)   

  M1        62.534   0.606                                11(44.0)                             14(56.0)    0.690          10(50.0)    10(50.0)    0.987       

  Grade     Low      81.664                                                                    76(32.3)    159(67.7)                  95(50.8)    92(49.2)    

            High     70.133                               0.233                                64(43.5)    83(56.5)       0.027^\*^   50(42.4)    68(57.6)    0.151
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

*P* value \< 0.05 was labeled with asterisk mark. G0 and N3 cases were excluded for analysis. Well differentiated to moderate differentiated cases were grouped as low grade while moderate-to-poorly differentiated to poorly differentiated cases were grouped as high grade.

DISCUSSION {#s3}
==========

EGFR is well-known as oncogenic signal regulating proliferation apoptosis and differentiation and thereby contributes to carcinogenesis. The development of specific small molecules and antibodies targeted to EGFR represents an attractive clinical implementation \[[@R11], [@R12]\].

The reasons for EGFR overexpression are related with *EGFR* gene amplification, receptor-activating mutations, or deficiency of negative regulatory mechanisms \[[@R13]\]. Here, we investigated prognostic value of *EGFR* mRNA expression by mining the data deposited in the GEO and Oncomine databases. Although there are studies revealing that high *EGFR* mRNA \[[@R13]--[@R18]\] or even gene copy number \[[@R19]\] was correlated with poor clinical outcomes or pathological characteristics, a more systematic evaluation of published studies did not validate the proposed impact of *EGFR* mRNA expression. The inconsistency partially may be attributed to the choice of the *EGFR* probe. Microarray chips normally provided several probes targeting the same gene. Expression intensity according to different probes can extraordinarily differ, which may even lead to completely opposite conclusions. We used the optimal probe for our analysis based on the concept of jetset probe \[[@R20]\], which means only those probes providing comparatively better overall specificity, coverage and robustness were chosen. Since no correlation was found based on mRNA expression, we assessed 30 independent studies assuming that EGFR protein expression might be a more promising prognostic factor than *EGFR* mRNA expression.

As demonstrated by elegant analyses, there exist two distinct patterns of EGFR expression. Upon stimulation with ligands, mcEGFR undergoes COPI-mediated retrograde trafficking from the Golgi apparatus to the endoplasmic reticulum. With the help of importin β1 and Sec61β, mcEGFR can be shuttled from outer nuclear membrane to inner nuclear membrane and finally released into nucleoplasm and become nEGFR \[[@R21], [@R22]\]. Therefore, we took one step further and investigated, whether protein expression patterns as membranous and cytoplasmic or nuclear expression would make a difference in regard of affecting clinical outcomes or pathological characteristics. Although it has been reported that once entered into nucleus, nEGFR functions in a manner distinct from its cytoplasmic membrane counterpart \[[@R9], [@R23], [@R24], [@R10], [@R25]--[@R27]\], we primarily focused on clarifying the relationship between mcEGFR and nEGFR. In the current study, we observed a clear positive correlation between mcEGFR and nEGFR (*p* \< 0.001). Furthermore, both mcEGFR and nEGFR expressions were unexpectedly associated with T stage in an adverse manner (*p* \< 0.001 and *p* = 0.004; respectively). Positive mcEGFR was related to well differentiation (*p* = 0.027). We also revealed the diverse distribution patterns of both mcEGFR and nEGFR within different tumor types.

Taken together, our results indicated that protein rather than mRNA expression reflects the prognostic value of EGFR. This may have important implications, since results based on *EGFR* expression obtained by mRNA microarray and next generation sequencing technologies may be less informative than those resulting from protein arrays or immunohistochemical analyses. Recently, the nuclear expression of EGFR came more into the focus of attention, which can be only monitored by methods based on protein visualization and localization. Furthermore, the fact that both mcEGFR and nEGFR expression was rather associated with low T stage and positive mcEGFR was related to low grade, thus high tissue differentiation, may imply that the oncogenic function of EGFR may be more related to nascent stages of carcinogenesis than to advanced and progressive tumors, which may as well explain at least partially the occurrence of secondary resistance against EGFR-directed therapy.

MATERIALS AND METHODS {#s4}
=====================

Tumor cases {#s4_1}
-----------

A total number of 502 formalin-fixed and paraffin-embedded tumor cases covering 27 tumor types have been obtained from different sources: Ovarian and endometrial carcinoma biopsies were provided by Prof. Jose Schneider and belong to the tumor banks of Hospital Universitario de Cruces, Bilbao, Spain and Hospital Universitario Valdecilla, Santander, Spain, respectively, and were to a large extent used in previous studies on oncogenic activation in gynecologic tumors \[[@R28], [@R29]\]. Relevant data and ethical approval by Wandsworth Ethics Committee (Wandsworth, UK, Ref: 08/H0803/3) regarding colon cancer has been published by us \[[@R30]\]. Further tumor biopsies have been obtained from Dr. Zahir Yassin (Tayba Cancer Centre, Khartoum, Sudan) with ethical approval from the National Medicines ans Poisons Board, Sudan (dated: September 20, 2015; Ref.: TQM/Pir-F/4). In addition, two tissue microarrays (TMAs) BC000119 (Biomax Inc., Derwood, USA) and T8235713 (Biocat, Heidelberg, Germany) were commercially available. Three further TMAs were provided by the Tissue Bank of the Institute of Pathology, University Medical Center, Mainz, Germany) with ethical approval from The Ethics Committee of the State Authorization Association for Medical Issues (*Landesärtzekammer)* Rheinland Pfalz (dated: March 22, 2018; Ref. 2018-13179). All patients gave informed consent prior to participation. All tumor cases information refers to [Supplementary Table 1](#SD2){ref-type="supplementary-material"}.

Statistical evaluation of the GEO and Oncomine databases {#s4_2}
--------------------------------------------------------

*EGFR* mRNA expression data and corresponding overall survival time, TNM stage and grade information were obtained from the GEO (<https://www.ncbi.nlm.nih.gov/geo/>) and Oncomine (<https://www.oncomine.org/>) databases. Normalized and log-2 transformed *EGFR* mRNA expression values of jetset probes were further determined as "low" or "high" using both median and mean as the cut-off value. Thirty datasets covering 15 cancer types were analyzed for time-to-event distributions estimated with Kaplan--Meier curves with log-rank test as assessing significance method. Associations of *EGFR* mRNA expression level with pathological characteristics were determined by Pearson\'s χ2-test. The above mentioned statistical analyses were performed using IBM SPSS Statistics version 23 (IBM, USA). Statistical differences with *p*-values less than 0.05 were considered as significant.

Search strategy {#s4_3}
---------------

Thirty independent studies \[[@R14], [@R19], [@R31]--[@R58]\] based on immunohistochemical EGFR determination from Pubmed engine (<https://www.ncbi.nlm.nih.gov/pubmed>) were identified by combining the search terms "EGFR", "expression", "predictor", "biomarker" and "prognosis/prognostic" for estimating EGFR protein expression and its correlation with clinical outcomes in comparison to analyses derived from the GEO and Oncomine databases based on mRNA expression.

Immunohistochemistry and statistical application {#s4_4}
------------------------------------------------

Immunohistochemistry was performed on 502 biopsies using EGFR rabbit monoclonal antibody (Clone EP38Y; Thermo Fisher Scientific, Dreieich, Germany) as primary antibody. The staining procedure has been previously published by us \[[@R59]\]. Quantification of immunostainings was performed by using Panoramic Desk (3D Histotech Panoramic digital slide scanner, Budapest, Hungary). Membranous and cytoplasmic EGFR (mcEGFR) was quantified by MembraneQuant software by using H-Score. A minimum of each three representative areas per tumor were scanned and the mean values together with standard deviations were calculated. One-hundred-four cases were excluded for nuclear EGFR (nEGFR) analysis due to the limitation in distinguishing extremely positive mcEGFR and existence of nEGFR. The other 398 cases were manually graded regarding nEGFR expression.

We used one-way ANOVA to exert mean comparison of mcEGFR H-score within different cancer types, TNM stage and grade, respectively. Independent *t*-test was used to determine variation in distribution of mcEGFR H-score in nEGFR negative and positive groups. mcEGFR and nEGFR were further categorized into four degrees or negative and positive groups according to expression intensity. As to mcEGFR H-scores, values below 20 were grouped as negative; H-scores ranging from 20 to 115 as weakly positive, from 115 to 210 as moderate positive and above 210 as strongly positive. The later three groups were all considered as positive. The signal-to-noise cutoff of mcEGFR H-score was determined by H-score obtained from negative controls (omission of primary antibody during staining procedure). nEGFR was similarly grouped as negative, weak, moderate and strong positive immunostaining or as negative and positive groups. As categorical data, both mcEGFR and nEGFR and their association with pathological TNM stage and grade was assessed by Pearson's χ2-test. Above statistical analyses were performed by using IBM SPSS Statistics version 23 (IBM, USA). Statistical differences with *p*-values less than 0.05 were considered as significant. Noticeably, as to grade-relevant analyses, cases graded as G0 were excluded, well differentiated to moderate differentiated cases were grouped as low grade, while moderate-to-poorly differentiated to poorly differentiated cases were grouped as high grade.
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AKT

:   Protein kinase B

DFS

:   disease-free survival

EGF

:   epidermal growth factor

EGFR

:   epidermal growth factor receptor

ERK

:   extracellular signal--regulated kinase

HER

:   human epidermal growth factor receptor

MAPK

:   mitogen-activated protein kinase

mcEGFR

:   membranous and cytoplasmic epidermal growth factor receptor

nEGFR

:   nuclear epidermal growth factor receptor

OS

:   overall survival

PFS

:   progression-free survival

PI3K

:   Phosphatidylinositol-4: 5-bisphosphate 3-kinase

PKC

:   protein kinase C

PLCγ1

:   Phosphoinositide-specific phospholipase C

TGF-α

:   transforming growth factor α

TKI

:   tyrosine kinase inhibitor

TMA

:   Tissue Microarray

TRK

:   tyrosine kinase receptors.
